CSTONE PHARMA-B's stock surged 6.73% during intraday trading, reflecting strong investor optimism following recent positive clinical updates and a significant analyst action.

The movement is primarily attributed to the company's announcement of positive preliminary efficacy data from the Phase I/II trial of its trispecific antibody candidate, CS2009, as a monotherapy for lung cancer. CStone Pharma plans to initiate the first global multi-center Phase III clinical trial for CS2009 by the end of 2026, targeting indications including non-small cell lung cancer, colorectal cancer, and small cell lung cancer.

Concurrently, China Merchants Securities International issued a research report dramatically raising its target price for CStone Pharma by 131.5% to HK$16.9, while maintaining an "Add" rating. The upgrade reflects an increased valuation for the CS2009 asset, with the institution highlighting the company's clear research and development strategy and the potential for deep collaboration with major overseas pharmaceutical companies.